You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)完成收購山東博安股權
格隆匯 02-17 22:34

格隆匯2月17日丨綠葉製藥(02186.HK)發佈公告,有關收購山東博安股權,所有完成條件均已達成,而完成於2020年2月17日落實。

隨着集團展望下一階段發展及發展成為一家全球創新制藥公司,集團認為,持續投資創新、先進技術對集團的長期成功至關重要。透過戰略收購山東博安(一家在生物類似藥及創新藥研發方面擁有出色往績記錄的公司),集團希望不僅進一步擴展及多元化其在研產品線,亦希望進一步加快其在快速增長的生物製藥細分領域的增長及滲透。

董事會認為,收購事項與集團透過收購加快集團業務增長及產品組合的策略聲明及成為全球領先製藥公司的終極目標一致。近年來,數家中國製藥公司已公佈其於抗體產品方面的進展或投資,包括申請市場銷售批准及開始相關臨牀試驗。因此,為維持集團於該細分領域的領先地位及確保其長期可持續增長,集團過去已收購四種博安生物類似藥以持續構建其生物抗體產品線,現時正尋求達成收購山東博安的98.0%股權,以進一步拓寬其創新生物抗體候選藥物組合及增強其現時於該細分領域的研發及生產能力。

鑑於山東博安的產品及技術對集團而言屬補充性質,董事會亦認為兩間公司可在多個領域合作及達到顯著的協同效應,包括但不限於具類似或共同適應症及研發的藥物的銷售及市場推廣。整體而言,董事會對收購事項可迎來的新機遇充滿期待,且董事會相信收購事項將為公司及其股東帶來價值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account